Byeong-Geon Lee

Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL.

LG Management Development Institute Co., Ltd. provides management advisory services. The company was founded in 1986 and is headquartered in Kyonggi, South Korea.

Stemedica Cell Technologies, Inc. operates as a biotechnology company that manufactures adult allergenic stem cells. Its adult stem cells which are used by research institutions and hospitals for pre-clinical and clinical studies. It has offices in Mexico, Italy, Switzerland, and France. The company was founded by Roger J. Howe and Maynard A. Howe in 2005 and is headquartered in San Diego, CA.

Aquavit Pharmaceuticals, Inc. operates as a healthcare company that discovers, develops, and commercializes therapeutic products. It offers pharmaceuticals, nutraceuticals, and biologics. The company was founded in October 2010 and is headquartered in New York, NY.

CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC.

Hapln Science Co. Ltd. is a drug development company, which focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company was founded on November 22, 2018 and is headquartered in Seongnam, South Korea.